HR 3029 Aims to Mandate NIST Standards for Synthetic Nucleic Acid Screening
Data as of August 18, 2026 · Refresh this data →
Sponsored by Rep. Salinas, Andrea [D-OR-6] · 3 cosponsors
Plain-English Summary
Nucleic Acid Standards for Biosecurity Act This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis. Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents). The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.) In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress. NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.
Current Status
Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
What Problem This Addresses
Current synthetic nucleic acid services lack uniform screening protocols, creating gaps that could be exploited to produce harmful biological agents. Existing voluntary measures do not provide a consistent, measurable framework for assessing the safety of custom DNA or RNA orders. The rapid growth of engineering biology and the integration of artificial‑intelligence tools increase both the speed and complexity of potential misuse. Without federal coordination, stakeholders have no mandated mechanism for operational security or conformity assessment. The bill seeks to fill that gap by directing NIST to conduct measurement research, convene stakeholder groups, and periodically update consensus standards.
Outlook
The measure cleared the House by voice vote under suspension of the rules, indicating bipartisan procedural support. It has now been read twice in the Senate and assigned to the Committee on Commerce, Science, and Transportation, where it will compete with a crowded agenda. With only three cosponsors and no evident Senate co‑sponsor, the bill faces an uncertain path to floor consideration. If the Commerce Committee advances it, a typical timeline would place a Senate vote in the second half of the 119th Congress, but the lack of high‑profile backing suggests it could stall. Consequently, analysts assess that passage is possible but not assured.
Arguments From Supporters
Proponents argue that standardized screening can prevent the accidental or intentional synthesis of pathogenic DNA or RNA, strengthening national biosecurity. NIST’s technical expertise and its recent AI‑related executive‑order mandate position it as the logical lead agency for creating scientifically robust standards. By establishing consensus priorities through stakeholder engagement, the bill aims to balance security with the needs of legitimate research and commercial development. Supporters also note that consistent conformity assessment can facilitate international collaboration and trade in synthetic biology products.
Arguments From Opponents
The record does not identify organized opposition, but industry groups could view mandatory standards as an added compliance cost. Critics might contend that prescriptive federal guidelines could slow innovation in a fast‑moving sector. Some legislators could be wary of expanding NIST’s scope into biosecurity, arguing that existing voluntary frameworks are sufficient. No formal objections were recorded during House debate, leaving the extent of opposition uncertain.
Where Both Sides Agree
Both supporters and potential critics agree that the rapid expansion of synthetic nucleic acid technologies creates new biosecurity considerations. There is consensus that some form of coordinated guidance, whether voluntary or mandated, would improve consistency across providers. Stakeholders broadly accept NIST’s technical capacity to lead standard‑setting efforts.
Core Disagreement
The primary disagreement centers on whether mandatory, federally‑backed standards are necessary versus relying on industry‑self‑regulation. Opponents worry about regulatory burden and possible delays, while supporters emphasize the risk of unchecked misuse. The scope of NIST’s authority to address AI‑linked risks in engineering biology also generates debate.
Constitutional Basis Cited
The sponsor cites Article I, Section 8, Clause 3 of the Constitution, granting Congress power to regulate interstate commerce, as the basis for authorizing NIST’s activities. This commerce clause authority is commonly used for federal standard‑setting in science and technology, suggesting no immediate constitutional obstacle. No substantive constitutional challenges have been raised in the legislative record, and the bill’s focus on measurement research and stakeholder coordination is unlikely to trigger preemption concerns.
Economic Considerations
The bill does not provide an official cost estimate, so any fiscal impact must be inferred. NIST will likely need additional funding to conduct measurement research, convene stakeholder meetings, and produce periodic reports, representing a modest increase in the agency’s budget. Synthetic biology companies may incur compliance expenses to align with new screening protocols, though standardized procedures could also reduce duplicated efforts across firms. If successful, the standards could lower long‑term biosecurity incident costs, offering a net societal benefit that outweighs short‑term implementation costs. Overall, analysts expect the economic impact to be modest but measurable, contingent on the breadth of the standards adopted.
Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced legislative record from Congress.gov, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.
← All Records